EGFR and non-small cell lung carcinoma: Treatment with first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) had prolonged the median progression-free survival (PFS) to 9.2–14.7 months in EGFR mutated advanced NSCLC patients [3–7], which was superior to chemotherapy and changed the treatment landscape of NSCLC dramatically.